CYTK.NASDAQCytokinetics INC

Form 4: Cytokinetics CFO Sells Shares for Tax Obligations

Sentiment:

Insider Transaction Report


Cytokinetics' EVP and CFO, Sung Lee, sold 4,935 shares of common stock at $62.15 per share to cover tax withholding obligations related to RSU vesting.

Summary

  • Sung Lee, Executive Vice President and Chief Financial Officer of Cytokinetics Inc. (CYTK), reported a transaction on March 17, 2026.
  • The transaction involved the sale of 4,935 shares of common stock at a price of $62.15 per share.
  • This sale was a compelled 'sell-to-cover' transaction, executed to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs).
  • Following this transaction, Sung Lee beneficially owns 87,127 shares of Cytokinetics common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as 'sell-to-cover' transactions for tax obligations are routine and non-discretionary, not reflecting a change in management's confidence.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a standard and common practice for executives receiving equity compensation, such as Restricted Stock Units (RSUs), to meet tax liabilities upon vesting. This type of transaction is generally not indicative of management's sentiment towards the company's future prospects.

Stakeholder Impact

  • Shareholders: The transaction represents a minor reduction in direct insider ownership, but for a non-discretionary tax-related reason, which typically has minimal impact on investor sentiment.

Key Dates

DateDescription
03/17/2026Transaction Date: Sale of common stock by Sung Lee.
03/18/2026Signature Date of the reporting person's attorney-in-fact.

Recommendation

hold

The transaction is a routine, non-discretionary 'sell-to-cover' to satisfy tax obligations from RSU vesting. It does not reflect a change in management's view of the company's prospects or fundamental value. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

CYTK, Cytokinetics, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Sung Lee

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.